151 related articles for article (PubMed ID: 15204421)
1. The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment.
Gjengstø P; Eide J; Frugård J; Bakke A; Høisaeter PA
Scand J Urol Nephrol; 2004; 38(1):15-8. PubMed ID: 15204421
[TBL] [Abstract][Full Text] [Related]
2. [The general practitioner's part in the initiation of diagnostic procedures in prostate cancer].
Braun KP; May M; Grassmel Y; Führer S; Hoschke B; Braun V
Aktuelle Urol; 2008 Mar; 39(2):141-6. PubMed ID: 18379968
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
Jønler M; Eddy B; Poulsen J
Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
[TBL] [Abstract][Full Text] [Related]
4. [The assessment of pathological PSA values by the general practitioner--observation or intervention?].
Braun KP; Brookman-Amissah S; May M; Grassmel Y; Hoschke B; Braun V
Aktuelle Urol; 2009 May; 40(3):171-4. PubMed ID: 19479670
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
6. [One man of five aged 50 years and over referred to a urologist is diagnosed with cancer. PSA analysis is important for correct prioritization of the referrals].
Boman H; Hedelin H
Lakartidningen; 2005 May 16-22; 102(20):1519-21. PubMed ID: 15973877
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
8. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
11. [PSA: the difficult position of general practitioners between patients and urologists].
Vincendeau S; Abi Moussa M; Manunta A; Patard JJ; Guillé F; Lobel B
Prog Urol; 2003 Apr; 13(2):252-5. PubMed ID: 12765060
[TBL] [Abstract][Full Text] [Related]
12. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
14. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
15. Abnormal PSA tests--delays in referral.
Stapleton AM; Johns RL; Kopsaftis T; Tamblyn DJ; Pinnock CB
Aust Fam Physician; 2008; 37(1-2):84-8. PubMed ID: 18239761
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of prostate cancer detected by digital rectal examination only.
Okotie OT; Roehl KA; Han M; Loeb S; Gashti SN; Catalona WJ
Urology; 2007 Dec; 70(6):1117-20. PubMed ID: 18158030
[TBL] [Abstract][Full Text] [Related]
18. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
[TBL] [Abstract][Full Text] [Related]
19. Prognostic features in men who died of prostate cancer.
Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
[TBL] [Abstract][Full Text] [Related]
20. Are doctors examining prostates in university hospital?
Lim CH; Quinlan DM
Urology; 2007 Nov; 70(5):843-5. PubMed ID: 18068436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
